Skip Ribbon Commands
Skip to main content

Prof Cook Stuart Alexander

Prof Stuart Cook from National Heart Centre Singapore

Prof Cook Stuart Alexander


Senior Consultant

Tanoto Foundation Professor of Cardiovascular Medicine

Specialty: Cardiology

Sub-specialties: Cardiac Magnetic Resonance Imaging

Conditions Treated by this Doctor:
Magnetic Resonance Imaging (MRI) Scan.

Clinical Appointments

  • Director, National Heart Research Institute Singapore
  • Deputy Director (Clinical), SingHealth Duke-NUS Institute of Precision Medicine
  • Tanoto Foundation Professor of Cardiovascular Medicine Department of Cardiology National Heart Centre SingaporeNational Heart Centre Singapore

Academic Appointments

  • Academic Vice Chair, Research SingHealth Duke-NUS Cardiovascular Sciences Academic Clinical Programme


Prof Stuart Cook is the Tanoto Foundation Professor of Cardiovascular Medicine at the SingHealth Duke-NUS Academic Medical Centre, and a Distinguished Clinician Scientist and Senior Consultant with the Department of Cardiology at the National Heart Centre Singapore (NHCS). He is also Director of the National Heart Research Institute Singapore; Deputy Director (Clinical) of the SingHealth Duke-NUS Institute of Precision Medicine (PRISM); Director of the Cardiovascular and Metabolic Disorders Programme at Duke-NUS Medical School, and Academic Vice Chair of Research in the Cardiovascular Sciences Academic Clinical Programme.

Prof Cook's sub-specialty interest is in Cardiac Magnetic Resonance Imaging (MRI). He is an internationally recognised expert in cardiovascular research, and his research focuses on the genetics of cardiovascular disease with a particular interest in inherited cardiac conditions that cause electrical abnormalities of the heart and heart failure. In October 2012, he received the prestigious STaR Investigator Award from the National Medical Research Council for his outstanding qualifications in translational and clinical research.


Prof Cook qualified in medicine at St Bartholomew’s hospital, London, UK. He completed house jobs in London, obtained his MRCP and then did a PhD at the National Heart and Lung Institute, Imperial College, UK.

Prof Cook undertook a three-year Post Doctoral training post at Harvard, Boston, USA funded by a Wellcome Trust International Prize Travelling Fellowship. He was awarded a Department of Health Clinical Scientist Award in 2004.

In 2008, he was appointed as Senior Lecturer at Imperial College, Group Head in the MRC Clinical Sciences Centre and Honorary Consultant at the Hammersmith Hospital, where he set up the cardiology MRI service.

In 2009, he was appointed as Head of Genetics at the Cardiovascular Biomedical Research Unit at the Royal Brompton NHS Trust. He was made Professor of Clinical and Molecular Cardiology at Imperial College the following year.

Prof Cook is an expert in Cardiac MRI. He has a special interest in the genetics and heart muscle disease and the application of new imaging and sequencing technologies to diagnose and treat heart disease.

Professional Appointments and Committee Memberships

Prof Cook is the Professor of Clinical and Molecular Cardiology at Duke-NUS where he heads a team of scientists. He is also Deputy Director of the cardiovascular Biomedical Research Unit, Royal Brompton Hospital, and a Professor of Cardiology at the National Heart and Lung Institute, London, UK.


  • Singapore Translational Research Investigator Award, National Medical Research Council, 2018​
  • STaR Investigator Award from the National Medical Research Council, Oct 2012 

Research Interests

  • ​Genetics and heart muscle disease
  • Application of new imaging and sequencing technologies to diagnose and treat heart disease

Publications and Research Trials

  • Integrative genomics in cardiovascular medicine. Ware, J. S., Petretto, E. & Cook, S. A. Cardiovasc Res (2012). In press
  • Next Generation Diagnostics in Inherited Arrhythmia Syndromes. Ware, J. S. et al. J Cardiovasc Transl Res (2012). in press
  • Paralogous annotation of disease-causing variants in long QT syndrome genes. Ware, J. S., Walsh, R., Cunningham, F., Birney, E. & Cook, S. A. Hum. Mutat. 33, 1188–1191 (2012).
  • Left ventricular remodelling and hypertrophy in patients with aortic stenosis: insights from cardiovascular magnetic resonance. Dweck, M. R. et al. J Cardiovasc Magn Reson 14, 50 (2012).
  • Remodeling after acute myocardial infarction: mapping ventricular dilatation using three dimensional CMR image registration. O'Regan, D. P. et al. J Cardiovasc Magn Reson 14, 41 (2012).
  • Truncations of titin causing dilated cardiomyopathy. Herman, D. S. et al. N. Engl. J. Med. 366, 619–628 (2012).
  • Next generation sequencing for clinical diagnostics and personalised medicine: implications for the next generation cardiologist. Ware, J. S., Roberts, A. M. & Cook, S. A. Heart (2011).doi:10.1136/heartjnl-2011-300742
  • Endonuclease G is a novel determinant of cardiac hypertrophy and mitochondrial function. McDermott-Roe, C. et al. Nature 478, 114–118 (2011).
  • Bayesian Detection of Expression Quantitative Trait Loci Hot-spots. Bottolo, L. et al. Genetics (2011).doi:10.1534/genetics.111.131425
  • Midwall fibrosis is an independent predictor of mortality in patients with aortic stenosis. Dweck, M. R. et al. Journal of the American College of Cardiology 58, 1271–1279 (2011).
  • Myocarditis or myocardial infarction? MRI can help. O'Regan, D. P. & Cook, S. A. Heart 97, 1283 (2011).
  • A genome-wide association study identifies two loci associated with heart failure due to dilated cardiomyopathy. Villard, E. et al. Eur. Heart J. 32, 1065–1076 (2011).
  • EndoG links Bnip3-induced mitochondrial damage and caspase-independent DNA fragmentation in ischemic cardiomyocytes. Zhang, J. et al. PLoS ONE 6, e17998 (2011).
  • Assessment of severe reperfusion injury with T2* cardiac MRI in patients with acute myocardial infarction. O'Regan, D. P. et al. Heart 96, 1885–1891 (2010).
  • A trans-acting locus regulates an anti-viral expression network and type 1 diabetes risk. Heinig, M. et al. Nature 467, 460–464 (2010).
  • MicroRNA-223 regulates Glut4 expression and cardiomyocyte glucose metabolism. Lu, H., Buchan, R. J. & Cook, S. A. Cardiovasc Res 86, 410–420 (2010).
  • New insights into the genetic control of gene expression using a Bayesian multi-tissue approach. Petretto, E. et al. PLoS Comput Biol 6, e1000737 (2010).
  • Abnormal myocardial insulin signalling in type 2 diabetes and left-ventricular dysfunction. Cook, S. A. et al. Eur. Heart J. 31, 100–111 (2010).
  • Myostatin inhibits IGF-I-induced myotube hypertrophy through Akt. Morissette, M. R., Cook, S. A., Buranasombati, C., Rosenberg, M. A. & Rosenzweig, A. Am J Physiol, Cell Physiol 297, C1124–32 (2009).
  • Genomic analysis of left ventricular remodeling. Sarwar, R. & Cook, S. A. Circulation 120, 437–444 (2009).
  • Cardiac MRI of myocardial salvage at the peri-infarct border zones after primary coronary intervention. O'Regan, D. P. et al. Am J Physiol Heart Circ Physiol 297, H340–6 (2009).
  • Reperfusion hemorrhage following acute myocardial infarction: assessment with T2* mapping and effect on measuring the area at risk. O'Regan, D. P. et al. Radiology 250, 916–922 (2009).
  • Are transgenic mice the ‘alkahest’ to understanding myocardial hypertrophy and failure? Cook, S. A., Clerk, A. & Sugden, P. H. J Mol Cell Cardiol 46, 118–129 (2009).
  • Distribution and functional impact of DNA copy number variation in the rat. Guryev, V. et al. Nat Genet 40, 538–545 (2008).
  • Soluble epoxide hydrolase is a susceptibility factor for heart failure in a rat model of human disease. Monti, J. et al. Nat Genet 40, 529–537 (2008).
  • Integrated genomic approaches implicate osteoglycin (Ogn) in the regulation of left ventricular mass. Petretto, E. et al. Nat Genet 40, 546–552 (2008).
  • Genome-wide co-expression analysis in multiple tissues. Grieve, I. C. et al. PLoS ONE 3, e4033 (2008).
  • Heritability and tissue specificity of expression quantitative trait loci. Petretto, E. et al. PLoS Genet 2, e172 (2006).
  • Myostatin regulates cardiomyocyte growth through modulation of Akt signaling. Morissette, M. R. et al. Circulation Research 99, 15–24 (2006).
  • Fas-associated death-domain protein inhibits TNF-alpha mediated NF-kappaB activation in cardiomyocytes. Chao, W. et al. Am J Physiol Heart Circ Physiol 289, H2073–80 (2005).
  • Integrated transcriptional profiling and linkage analysis for identification of genes underlying disease. Hubner, N. et al. Nat Genet 37, 243–253 (2005).
  • Integrin-linked kinase regulates endothelial cell survival and vascular development. Friedrich, E. B. et al.Mol. Cell. Biol. 24, 8134–8144 (2004).
  • A20 is dynamically regulated in the heart and inhibits the hypertrophic response. Cook, S. A., Novikov, M. S., Ahn, Y., Matsui, T. & Rosenzweig, A. Circulation 108, 664–667 (2003).
  • DNA microarrays: implications for cardiovascular medicine. Cook, S. A. & Rosenzweig, A. Circulation Research 91, 559–564 (2002).
  • Phenotypic spectrum caused by transgenic overexpression of activated Akt in the heart. Matsui, T. et al. J. Biol. Chem. 277, 22896–22901 (2002).
  • Transcriptional effects of chronic Akt activation in the heart. Cook, S. A., Matsui, T., Li, L. & Rosenzweig, A. J. Biol. Chem. 277, 22528–22533 (2002).
  • Interpretation of transcript profiling. Rosenzweig, A. & Cook, S. Circulation Research 89, E40 (2001).
  • Regulation of bcl-2 family proteins during development and in response to oxidative stress in cardiac myocytes: association with changes in mitochondrial membrane potential. Cook, S. A., Sugden, P. H. & Clerk, A. Circulation Research 85, 940–949 (1999).
  • Activation of c-Jun N-terminal kinases and p38-mitogen-activated protein kinases in human heart failure secondary to ischaemic heart disease. Cook, S. A., Sugden, P. H. & Clerk, A. J Mol Cell Cardiol 31, 1429–1434 (1999).

Research Trials